research
∙
10/17/2022
A Bayesian design for dual-agent dose optimization with targeted therapies
In this article, we propose a phase I-II design in two stages for the co...
share
research
∙
08/11/2022
Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?
In parametric Bayesian designs of early phase cancer clinical trials wit...
research
∙
09/29/2021
Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials
Phase I-II cancer clinical trial designs are intended to accelerate drug...
research
∙
01/10/2021
Visualizing adverse events using correspondence analysis
We propose to apply stacked CA using contribution biplots as a tool to e...
research
∙
10/21/2019
A Nonparametric Bayesian Design for Drug Combination Cancer Trials
We propose an adaptive design for early phase drug combination cancer tr...
research
∙
09/12/2018